Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Operations (2016 - 2025)

Ptc Therapeutics has reported Cash from Operations over the past 14 years, most recently at 34273000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 34273000.0 for Q4 2025, down 14.23% from a year ago — trailing twelve months through Dec 2025 was 711196000.0 (up 760.42% YoY), and the annual figure for FY2025 was 711196000.0, up 760.42%.
  • Cash from Operations for Q4 2025 was 34273000.0 at Ptc Therapeutics, up from 66301000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for PTCT hit a ceiling of 870103000.0 in Q1 2025 and a floor of 165963000.0 in Q4 2022.
  • Median Cash from Operations over the past 5 years was 53216000.0 (2021), compared with a mean of 8144800.0.
  • Biggest five-year swings in Cash from Operations: crashed 430.28% in 2024 and later surged 1129.64% in 2025.
  • Ptc Therapeutics' Cash from Operations stood at 68840000.0 in 2021, then plummeted by 141.09% to 165963000.0 in 2022, then skyrocketed by 39.57% to 100288000.0 in 2023, then soared by 70.08% to 30004000.0 in 2024, then dropped by 14.23% to 34273000.0 in 2025.
  • The last three reported values for Cash from Operations were 34273000.0 (Q4 2025), 66301000.0 (Q3 2025), and 58333000.0 (Q2 2025) per Business Quant data.